Low serum cholesterol levels predict inferior prognosis and improve NCCN‐IPI scoring in diffuse large B cell lymphoma

• Published in: International journal of cancer Vol. 143; no. 8; pp. 1884 - 1895
• Main Authors: Gao, Rui, Liang, Jin‐Hua, Wang, Li, Zhu, Hua‐Yuan, Wu, Wei, Cao, Lei, Fan, Lei, Li, Jian‐Yong, Yang, Tao, Xu, Wei
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 15.10.2018
• Subjects: Antineoplastic Agents - therapeutic use; B-cell lymphoma; Cancer; Cholesterol; Cholesterol - blood; Diagnosis; diffuse large B cell lymphoma; Disease-Free Survival; Female; High density lipoprotein; high‐density lipoprotein cholesterol; Humans; Kaplan-Meier Estimate; Low density lipoprotein; low‐density lipoprotein cholesterol; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - blood; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Medical prognosis; Medical research; Middle Aged; Monoclonal antibodies; Multivariate Analysis; NCCN‐IPI; Prognosis; Remission; Retrospective Studies; Rituximab; Rituximab - therapeutic use; Targeted cancer therapy; diffuse large B cell lymphoma; prognosis; low-density lipoprotein cholesterol; NCCN-IPI; high-density lipoprotein cholesterol

Low circulating cholesterol concentration is associated with elevated cancer incidence and mortality. However, the association between cholesterol levels and diffuse large B cell lymphoma (DLBCL) remains unknown. The aim of our study was to evaluate the prognostic value of serum lipid profile in DLB...